Tolerising antigen-specific immunotherapy for type 1 diabetes

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2002917

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We have developed a new immunotherapy to treat the underlying causes of type 1 diabetes (T1D) while leaving the rest of the immune system intact. To use this in patients, we need better tests to know when immune therapy is working. We will develop new methods to design the therapy and tools to track the relevant immune cells in T1D that work in variable patient groups. The knowledge gained will speed the pace of development and increase the chance of success of immunotherapy in T1D.

Funded Activity Details

Start Date: 01-01-2020

End Date: 01-01-2016

Funding Scheme: Ideas Grants

Funding Amount: $1,395,549.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

immune tolerance | regulatory t cells | t cell epitope | type 1 diabetes mellitus (insulin-dependent diabetes mellitus)

Related Links